Gornitzky represented the underwriters, led by Ladenburg Thalmann and Nomura Securities, in RedHill Biopharma’s USD 20 million underwritten public offering of American Depositary Shares (ADSs) on the NASDAQ Global Market.
RedHill Biopharma Ltd., a bio-pharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).
Ladenburg Thalmann and Nomura Securities acted as joint book-running managers. H.C. Wainwright acted as lead manager and LifeSci Capital, Ascendiant Capital Markets, SMBC Nikko Securities America and WBB Securities acted as co-managers for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Nir Knoll (Associate).